186 related articles for article (PubMed ID: 34258492)
1. Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.
Davidson CD; Bolf EL; Gillis NE; Cozzens LM; Tomczak JA; Carr FE
J Endocr Soc; 2021 Aug; 5(8):bvab102. PubMed ID: 34258492
[TBL] [Abstract][Full Text] [Related]
2. Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.
Bolf EL; Gillis NE; Davidson CD; Rodriguez PD; Cozzens L; Tomczak JA; Frietze S; Carr FE
Mol Cancer Res; 2020 Oct; 18(10):1443-1452. PubMed ID: 32554601
[TBL] [Abstract][Full Text] [Related]
3. TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice.
Gillis NE; Cozzens LM; Wilson ER; Smith NM; Tomczak JA; Bolf EL; Carr FE
Endocrinology; 2023 Aug; 164(10):. PubMed ID: 37702560
[TBL] [Abstract][Full Text] [Related]
4. Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.
Zhu X; Zhao L; Doolittle WKL; Cheng SY
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36939877
[TBL] [Abstract][Full Text] [Related]
5. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cancer stem cell activity by thyroid hormone receptor β.
Lee WK; Zhu X; Park S; Zhu YJ; Zhao L; Meltzer P; Cheng SY
Oncogene; 2022 Apr; 41(16):2315-2325. PubMed ID: 35256781
[TBL] [Abstract][Full Text] [Related]
7. Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
Furuya F; Lu C; Guigon CJ; Cheng SY
Steroids; 2009 Jul; 74(7):628-34. PubMed ID: 19014961
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
9. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Furuya F; Hanover JA; Cheng SY
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
11. Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.
Furuya F; Ying H; Zhao L; Cheng SY
Steroids; 2007 Feb; 72(2):171-9. PubMed ID: 17169389
[TBL] [Abstract][Full Text] [Related]
12. Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility.
Che HY; Guo HY; Si XW; You QY; Lou WY
Onco Targets Ther; 2014; 7():425-32. PubMed ID: 24665203
[TBL] [Abstract][Full Text] [Related]
13. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
Che HY; Guo HY; Si XW; You QY; Lou WY
Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
[TBL] [Abstract][Full Text] [Related]
14. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
15. GAB1 is upregulated to promote anaplastic thyroid cancer cell migration through AKT-MDR1.
Song P; Xu H; He Y; Sun J; Xu Z; Huang P; Ge M; Zhang X; Ke Y; Cheng H
Biochem Biophys Res Commun; 2022 Jun; 607():36-43. PubMed ID: 35366541
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone receptor β suppresses SV40-mediated tumorigenesis via novel nongenomic actions.
Kim DW; Zhao L; Hanover J; Willingham M; Cheng SY
Am J Cancer Res; 2012; 2(5):606-19. PubMed ID: 22957312
[TBL] [Abstract][Full Text] [Related]
17. Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β.
Park JW; Zhao L; Willingham MC; Cheng SY
Mol Carcinog; 2017 Feb; 56(2):489-498. PubMed ID: 27254276
[TBL] [Abstract][Full Text] [Related]
18. The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.
Bolf EL; Gillis NE; Barnum MS; Beaudet CM; Yu GY; Tomczak JA; Stein JL; Lian JB; Stein GS; Carr FE
Horm Cancer; 2020 Feb; 11(1):34-41. PubMed ID: 31865591
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Hou P; Liu D; Shan Y; Hu S; Studeman K; Condouris S; Wang Y; Trink A; El-Naggar AK; Tallini G; Vasko V; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1161-70. PubMed ID: 17317825
[TBL] [Abstract][Full Text] [Related]
20. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
